Back to mobile site

Neurocrine Bio. (NBIX) PT Lowered to $214 at UBS, Buy Rating Maintained

September 29, 2026 9:12 AM EDT Send to a Friend
UBS analyst Ashwani Verma lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $214.00 (from $231.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login